Acadia Healthcare (NASDAQ:ACHC), the largest standalone behavioral healthcare provider in the U.S., faces a critical turnaround period after operational setbacks in 2025 and early 2026. Trading at $23.18 with a $2.13 billion market cap, the stock reflects investor uncertainty.
In Q1 2026, leadership changes aimed to stabilize operations. Debbie Osteen returned as CEO, and Larry Herod joined to reassess revenue cycle efforts. These moves followed the departure of COO Dr. Khan in November 2025.
The company cut earnings guidance three times in 2025, including a $49 million EBITDA reduction in December due to higher insurance costs. New York Medicaid changes are expected to impact EBITDA by $25-30 million in 2026.
Despite challenges, Q1 2026 results showed improvement. The company is deploying AI-driven billing technologies to enhance revenue cycle management. A target of $200 million in improvements from underperforming facilities has been set.
Long-term projections are optimistic: free cash flow expected to exceed $200 million by 2027, EBITDA reaching $832 million by 2030, and EPS of $4.00 by 2030. For FY2028, revenue is estimated at $3.78 billion with EBITDA of $708 million.
Risks include regulatory changes, leadership instability, and revenue cycle challenges. However, favorable demand trends and the company's scale provide competitive advantages. ACHC appears undervalued, with analysts forecasting FY2026 EPS of $1.48.
